Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway
Patients initiating GLP-1 RA treatment (semaglutide, liraglutide, tirzepatide) were propensity scorematched (1:1) with RA controls not receiving GLP-1 RA therapy, balancing demographics, BMI categories, cardiovascular comorbidities, immunosuppressive therapies, and cardiometabolic medications
Theres no specific interaction between Mounjaro and lupus, no published trial data in lupus populations, and no immune-modulating effect that would change how lupus is managed
According to MEDVi's own published terms of use, MEDVi is not a healthcare provider
Final Thoughts: A Promising Tool, But Not a One-Size-Fits-All Solution GLP-1 medications are a powerful option for addressing metabolic challenges that can affect fertility, especially in patients with PCOS or obesity
However, tirzepatide should not be used as a replacement for prescribed blood pressure medication unless a healthcare provider makes that change